Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AMG 193

Next Previous
X
Search
Drug Profile

AMG 193

Alternative Names: AMG-193; MTA Cooperative PRMT5 inhibitor

Latest Information Update: 24 Sep 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Amgen
  • Class Antineoplastics; Small molecules
  • Mechanism of Action PRMT5 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours
  • Phase I Biliary cancer; Gastrointestinal cancer; Non-small cell lung cancer; Pancreatic cancer

Most Recent Events

  • 23 Sep 2024 Amgen plans a phase II trial for Non-small cell lung cancer (Late-stage disease, Metastatic disease, Inoperable/Unresectable, Second-line therapy or greater) in September 2024 (PO) (NCT06593522)
  • 06 Aug 2024 AMG 193 receives Orphan Drug status for Pancreatic cancer in USA, in August 2024
  • 01 May 2024 Phase-I clinical trials in Biliary cancer (Combination therapy, Late-stage disease, Metastatic disease, Inoperable/Unresectable) in USA (PO) (NCT06360354)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top